Amgen Tour of California Announce Additional Anti-Doping Testing Protocols
4/30/10 – AEG, with the support of Amgen and the U.S. Anti-Doping Agency (USADA), today announced additional testing protocols for the fifth annual Amgen Tour of California as part of the race’s comprehensive anti-doping initiatives.
Designed to supplement the Union Cycliste Internationale’s (UCI) Biological Passport, a groundbreaking anti-doping tool based on the ongoing monitoring of a rider’s blood and urine, the race’s 2010 anti-doping program will include the following elements:
- UCI in-competition testing – Each day, testing will be conducted with the stage winner, current leader of the general classification and three other riders (chosen from the general field)
- Pre-race testing – Riders will have blood and urine samples collected prior to the race. For teams not involved in the UCI Biological Passport program, USADA is conducting pre-event, out-of-competition testing in the weeks leading up to the race; these tests have already begun
- USADA Registered Testing Pool (RTP) – Conducted by USADA, riders in the RTP are tested throughout the year, in the out-of-competition program, including the weeks leading up to the event
- Prohibited List – Samples will be screened for substances and methods included on the World Anti-Doping Agency Prohibited List, such as steroids, hormones (e.g. EPO), stimulants and various masking agents
- Testing – Sample collections may include both urine and blood, and samples will be tested for the presence of prohibited substances such as steroids, hormones (including EPO) and various masking agents, as well as indications of blood manipulation. Certain samples will include special analysis, such as the CIR test for synthetic testosterone and will be tested for CERA and hGH
- Storage – A number of urine and blood samples collected will be stored for up to eight years so that, in the event of new testing methods, samples can be reevaluated
- All participating teams are required to ensure that all team members, including coaches, trainers and support staff, are clear of any pending doping investigations at the time of the 2010 Amgen Tour of California. The roster of riders will be provided by the participating team and will then be submitted to USA Cycling and UCI to confirm that there are no open investigations prior to the race
“USADA commends the Amgen Tour of California for taking a proactive and comprehensive approach to its anti-doping efforts at this event,” said USADA CEO Travis T. Tygart. “We are committed to protecting clean athletes and preserving a level playing field for those who want to compete fairly and healthy, and are pleased to work with the event management to do our utmost to ensure this.”
”Amgen appreciates and shares AEG’s interest in running a clean race,” said Dr. Steve Elliott, Amgen scientific executive director. “We are pleased with the steps AEG has taken, in collaboration with USADA and UCI, to continue to strengthen the Amgen Tour of California’s anti-doping program.”
